Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy



Status:Active, not recruiting
Healthy:No
Age Range:18 - 99
Updated:1/30/2019
Start Date:December 16, 2014
End Date:July 31, 2019

Use our guide to learn which trials are right for you!

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy

A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance
Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose
Disease Has Not Progressed on First Line Platinum Based Chemotherapy

Approximately 145 patients will be randomised using an Interactive Voice Response System
/Interactive Web Response System (IVR/IWR system) in a 3:2 ratio (Olaparib:placebo) to the
treatments as specified below:

- Olaparib tablets p.o. 300 mg twice daily

- Matching placebo tablets p.o. twice daily Eligible patients will be those patients with
pancreas cancer previously treated for metastatic disease who have not progressed
following completion of at least 16 weeks (can be more) of first line platinum-based
chemotherapy. All patients must have a known deleterious or suspected deleterious
germline BRCA mutation to be randomised; this may have been determined prior to
enrolment into the study or may be assessed as part of the enrolment procedure for the
study (via centrally provided MyriadIntegrated BRAC.

Patients will be randomised within 6 weeks after their last dose of chemotherapy (last dose
is the day of the last infusion) and treatment started as soon as possible but no less than 4
and no more than 8 weeks of the last chemotherapy dose. At the time of starting protocol
treatment, all previous chemotherapy treatment should be discontinued.

Following randomisation, patients will attend clinic visits weekly for the first 4 weeks of
treatment (Days 8, 15, 22 and 29). Patients will then attend clinic visits every 4 weeks
whilst on study treatment. Patients should continue to receive study treatment until
objective radiological disease progression as per RECIST as assessed by the investigator and
as long as in the investigator's opinion they are benefiting from treatment and they do not
meet any other discontinuation criteria.

Once a patient has progressed the patient will be followed for second progression (PFS2)
every 8 weeks and then survival until the final analysis.

Key Inclusion Criteria

- Histologically or cytologically confirmed pancreas adenocarcinoma receiving initial
chemotherapy for metastatic disease and without evidence of disease progression on
treatment

- Patients with measurable disease and/or non-measurable or no evidence of disease
assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in
this study.

- Documented mutation in gBRCA1 or gBRCA2 that is predicted to be deleterious or
suspected deleterious

- Patients are on treatment with a first line platinum-based (cisplatin, carboplatin or
oxaliplatin) regimen for metastatic pancreas cancer, have received a minimum of 16
weeks of continuous platinum treatment and have no evidence of progression based on
investigator's opinion.

- Patients who have received platinum as potentially curative treatment for a prior
cancer (eg ovarian cancer) or as adjuvant/neoadjuvant treatment for pancreas cancer
are eligible provided at least 12 months have elapsed between the last dose of
platinum-based treatment and initiation of the platinum-based chemotherapy for
metastatic pancreas cancer.

Major Exclusion Criteria:

- gBRCA1 and/or gBRCA2 mutations that are considered to be non detrimental (eg,
"Variants of uncertain clinical significance" or "Variant of unknown significance" or
"Variant, favour polymorphism" or "benign polymorphism" etc.)

- Progression of tumour between start of first line platinum based chemotherapy for
metastatic pancreas cancer and randomisation.

- Cytotoxic chemotherapy or non-hormonal targeted therapy within 28 days of Cycle

1 Day 1 is not permitted.

- Exposure to an investigational product within 30 days or 5 half lives (whichever is
longer) prior to randomisation

- Any previous treatment with a PARP inhibitor, including Olaparib
We found this trial at
21
sites
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Campbelltown,
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Commack, NY
Click here to add this to my saved trials
?
mi
from
Gilbert, AZ
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
New Haven, CT
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Stanford, CA
Click here to add this to my saved trials